Medeze Group Public Company Limited (SET: MEDEZE) has announced an ambitious roadmap for 2026, aiming for 25% revenue growth to reach the 1,000 million baht milestone. Speaking at an Opportunity Day event hosted by the Stock Exchange of Thailand, the CFO outlined a multifaceted strategy focused on domestic market dominance, international franchising, and pioneering advanced medical innovations.
The company reported a solid performance for the 2025 fiscal year, achieving a total revenue of 776.41 million baht and a net profit of 196.38 million baht. A notable recovery was seen in the fourth quarter of 2025, where revenue grew by 4% to 188.41 million baht and profit rose 11% to 36.43 million baht compared to the previous quarter. This upward trend was supported by increasing demand for contracts, particularly for cord tissue and adipose tissue stem cell services.
A pivotal component of the 2026 plan is the establishment of “MEDEZE GPO Empower,” a joint venture with the Government Pharmaceutical Organization (GPO) to produce cell culture medium. The official cooperation agreement is set for 2026, with factory construction beginning in 2027 and commercial production slated for 2028.
Furthermore, the company is advancing its clinical trials for Advanced Therapy Medicinal Products (ATMPs) targeting osteoarthritis and skin rejuvenation, with registration targets set for late 2026.
Beyond domestic borders, MEDEZE is expanding its footprint with a signed franchise agreement in Mongolia and an upcoming service centre in the Philippines. To diversify its commercial portfolio, the company is also preparing to launch consumer-centric products, including a hair growth serum and stem cell-based creams.
Looking ahead to 2030, MEDEZE has set a high bar, targeting a six-fold increase in revenue and an eight-fold increase in profit. This vision assumes an average annual growth rate of 41% for revenue and 52% for profit, driven by the synergy of ATMPs, global franchising, and local production of cell culture media.
